OTCMKTSMKTS:IGNE

Igene Biotechnology Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.11 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.87
Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors; and analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. The company was formerly known as IGI Biotechnology, Inc. and changed its name to IGENE Biotechnology, Inc. in April 1986. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland.

Industry, Sector and Symbol

Stock Exchange OTCMKTSMKTS
Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTSMKTS:IGNE
CUSIPN/A
CIKN/A
Phone410-997-2599
Employees18
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

MarketRank

Overall MarketRank

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
30 days | 90 days | 365 days | Advanced Chart

Receive IGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for IGNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Igene Biotechnology (OTCMKTSMKTS:IGNE) Frequently Asked Questions

What stocks does MarketBeat like better than Igene Biotechnology?

Wall Street analysts have given Igene Biotechnology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Igene Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Igene Biotechnology's key executives?

Igene Biotechnology's management team includes the following people:
  • Mr. Joseph L. Downs, Chief Exec. Officer

Who are some of Igene Biotechnology's key competitors?

What is Igene Biotechnology's stock symbol?

Igene Biotechnology trades on the OTCMKTSMKTS under the ticker symbol "IGNE."

How do I buy shares of Igene Biotechnology?

Shares of IGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does Igene Biotechnology have?

Igene Biotechnology employs 18 workers across the globe.

What is Igene Biotechnology's official website?

The official website for Igene Biotechnology is www.igene.com.

How can I contact Igene Biotechnology?

The company can be reached via phone at 410-997-2599.


This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.